Valeant Pharmaceuticals International, Inc. (NYSE: VRX/TSX: VRX) completed its acquisition of Synergetics USA, Inc. (“Synergetics”) on October 15, 2015. For Investor Relations information on Valeant, click here.

Synergetics USA, Inc. designs, manufactures, and markets precision engineered microsurgical instruments, capital equipment and devices primarily for use in vitreoretinal surgery and neurosurgical applications. Its products are designed and manufactured to support micro or minimally invasive surgical procedures. In addition, it also designs and manufactures disposable and non-disposable supplies and accessories for use with these products.

Our goal is to become a global leader in the development, manufacture and marketing of precision-engineered, microsurgical instruments and capital equipment for use in minimally invasive ophthalmic and neurosurgical applications and to grow our product lines in other specialty surgical markets.

Synergetics had found a receptive market in ophthalmology-one which was ripe with new ideas. It was a golden opportunity for a newcomer who was able to respond quickly to the needs of its market with innovative designs to implement the latest surgical techniques.

Although 20 years have passed since its humble beginnings, the dedication to quality and service has not changed. Synergetics has since expanded its focus to include neurosurgical instrumentation and equipment as well as its established retinal line of products.

The foundation of Synergetics lies embedded in the Company’s belief that we can always improve on what came before. The Synergetics name has become synonymous with cutting-edge technology as evidenced by its growing list of patents and patents pending. Today, the Company owns in excess of 40 patents worldwide and has more patents pending than ever before, reflecting our ongoing commitment to innovation.